A Serum-Based Diagnostic Test to Identify Pediatric Septic Shock
Tech ID #: 379.4 CONNECT WITH A MANAGER FOR LICENSING
Prompt detection of septic shock in pediatric patients thereby reducing the mortality rates of patients.
Description of Technology
Pediatric septic shock is a significant worldwide problem with mortality estimates ranging from 10-50 per cent. Early diagnosis and treatment can substantially improve patient outcomes (for each hour that treatment is delayed, patient mortality risk increases by 40 per cent). Unfortunately, it is much more difficult to diagnose sepsis and predict mortality rates in pediatric patients when compared to adults. As such, this technology addresses an unmet need for prompt detection of septic shock in pedatric patients.
Researchers at the University of Calgary have developed a diagnostic test for the early evaluation of pediatric septic shock patients. The technology is based on serum metabolomics, or the identification of specific metabolite patterns in serum samples. The test can discriminate between septic shock and systemic inflammatory response syndrome (SIRS) in pediatric patients of different ages (infants, toddlers and school age children). The metabolic profiles can also be used to accurately predict patient mortality.
Patent - US 8,969,071 B2
- Accurate diagnostic test for pediatric septic shock among infants, toddlers and school age children
- Prediction of mortality in pediatric septic shock patients more accurately than the use of Pediatric Risk of Mortality (PRISM) scores
Stage Of Development
- Method can discriminate between septic shock, SIRS, and healthy controls providing quantitative treatment guidance
- Currently seeking validation with external patient cohort